After two previous rejections, the FDA has approved AstraZeneca’s excess potassium drug, Lokelma.
AstraZeneca bought the drug’s original developer, ZS Pharma, for $2.7 billion in 2015. The drug was rejected twice by the FDA — once in May 2016 and again in March 2017 — due to unspecified manufacturing issues.
The approval is a big one for AstraZeneca, as it will give the drugmaker a rival hyperkalemia drug to Vifor Pharma’s Veltassa.
Read the press release